GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005254710 | Cervix | CC | regulation of peptidase activity | 112/2311 | 461/18723 | 6.70e-13 | 3.08e-10 | 112 |
GO:005254810 | Cervix | CC | regulation of endopeptidase activity | 103/2311 | 432/18723 | 1.89e-11 | 5.14e-09 | 103 |
GO:004586110 | Cervix | CC | negative regulation of proteolysis | 80/2311 | 351/18723 | 2.88e-08 | 1.98e-06 | 80 |
GO:00513469 | Cervix | CC | negative regulation of hydrolase activity | 81/2311 | 379/18723 | 4.27e-07 | 1.67e-05 | 81 |
GO:00104669 | Cervix | CC | negative regulation of peptidase activity | 60/2311 | 262/18723 | 1.27e-06 | 4.34e-05 | 60 |
GO:001095110 | Cervix | CC | negative regulation of endopeptidase activity | 56/2311 | 252/18723 | 7.43e-06 | 1.74e-04 | 56 |
GO:005254715 | Cervix | HSIL_HPV | regulation of peptidase activity | 52/737 | 461/18723 | 8.35e-12 | 6.81e-09 | 52 |
GO:005254815 | Cervix | HSIL_HPV | regulation of endopeptidase activity | 48/737 | 432/18723 | 9.20e-11 | 3.70e-08 | 48 |
GO:004586115 | Cervix | HSIL_HPV | negative regulation of proteolysis | 36/737 | 351/18723 | 1.64e-07 | 1.02e-05 | 36 |
GO:001046614 | Cervix | HSIL_HPV | negative regulation of peptidase activity | 30/737 | 262/18723 | 1.66e-07 | 1.03e-05 | 30 |
GO:001095113 | Cervix | HSIL_HPV | negative regulation of endopeptidase activity | 29/737 | 252/18723 | 2.39e-07 | 1.44e-05 | 29 |
GO:005134614 | Cervix | HSIL_HPV | negative regulation of hydrolase activity | 37/737 | 379/18723 | 3.81e-07 | 2.06e-05 | 37 |
GO:0052547111 | Esophagus | ESCC | regulation of peptidase activity | 275/8552 | 461/18723 | 7.54e-10 | 1.88e-08 | 275 |
GO:0052548111 | Esophagus | ESCC | regulation of endopeptidase activity | 253/8552 | 432/18723 | 3.68e-08 | 6.78e-07 | 253 |
GO:0045861111 | Esophagus | ESCC | negative regulation of proteolysis | 195/8552 | 351/18723 | 1.13e-04 | 7.85e-04 | 195 |
GO:0051346110 | Esophagus | ESCC | negative regulation of hydrolase activity | 208/8552 | 379/18723 | 1.76e-04 | 1.14e-03 | 208 |
GO:001046620 | Esophagus | ESCC | negative regulation of peptidase activity | 140/8552 | 262/18723 | 6.73e-03 | 2.46e-02 | 140 |
GO:001095119 | Esophagus | ESCC | negative regulation of endopeptidase activity | 135/8552 | 252/18723 | 6.86e-03 | 2.51e-02 | 135 |
GO:005254720 | Oral cavity | OSCC | regulation of peptidase activity | 255/7305 | 461/18723 | 5.78e-13 | 2.75e-11 | 255 |
GO:005254820 | Oral cavity | OSCC | regulation of endopeptidase activity | 235/7305 | 432/18723 | 4.35e-11 | 1.40e-09 | 235 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
A2ML1 | SNV | Missense_Mutation | rs780281065 | c.2678G>A | p.Arg893Gln | p.R893Q | A8K2U0 | protein_coding | tolerated(0.4) | benign(0.023) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
A2ML1 | SNV | Missense_Mutation | rs774567479 | c.3375G>T | p.Lys1125Asn | p.K1125N | A8K2U0 | protein_coding | deleterious(0.05) | possibly_damaging(0.831) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
A2ML1 | SNV | Missense_Mutation | | c.670N>A | p.Val224Met | p.V224M | A8K2U0 | protein_coding | tolerated(0.1) | possibly_damaging(0.593) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
A2ML1 | SNV | Missense_Mutation | | c.3116C>T | p.Ala1039Val | p.A1039V | A8K2U0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A11N-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
A2ML1 | SNV | Missense_Mutation | novel | c.2967N>T | p.Glu989Asp | p.E989D | A8K2U0 | protein_coding | deleterious(0.01) | possibly_damaging(0.672) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
A2ML1 | SNV | Missense_Mutation | | c.1577N>T | p.Ser526Leu | p.S526L | A8K2U0 | protein_coding | tolerated(0.08) | benign(0.315) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
A2ML1 | SNV | Missense_Mutation | | c.3092N>T | p.Gly1031Val | p.G1031V | A8K2U0 | protein_coding | tolerated(0.09) | possibly_damaging(0.877) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
A2ML1 | SNV | Missense_Mutation | | c.3893N>G | p.Tyr1298Cys | p.Y1298C | A8K2U0 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-BG-A0M4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
A2ML1 | SNV | Missense_Mutation | novel | c.3915N>T | p.Gln1305His | p.Q1305H | A8K2U0 | protein_coding | deleterious(0.02) | benign(0.289) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
A2ML1 | SNV | Missense_Mutation | | c.52N>A | p.Glu18Lys | p.E18K | A8K2U0 | protein_coding | tolerated(0.48) | benign(0.005) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |